文献速递牙周病

磺脲类药物对牙周致病菌诱导炎症的影响

Effects of Sulfonylureas on Periodontopathic Bacteria-Induced Inflammation.
PubMed 文献 · J Dent Res · 2020-03-23

该研究在THP-1巨噬细胞样细胞中评估格列本脲对牙周致病菌诱导IL-1β分泌的作用,并在牙周炎大鼠模型中观察口服格列本脲的组织学效果。结果显示格列本脲抑制IL-1β分泌并减轻炎症细胞浸润和破骨细胞数量,提示靶向NLRP3通路可能抑制牙周病。

要点

  • 格列本脲抑制牙周致病菌诱导的IL-1β分泌,格列美脲也有类似作用。
  • 甲苯磺丁脲、格列齐特和二甲双胍未抑制IL-1β释放。
  • 大鼠模型中口服格列本脲减少炎症细胞浸润和牙槽骨破骨细胞数量。

核心结论

  • 药理学靶向NLRP3通路可能是抑制牙周病的策略。

研究设计与样本

  • 体外使用THP-1细胞分化为巨噬细胞样细胞,经牙周致病菌刺激并加格列本脲处理。
  • 体内建立牙周炎大鼠模型,经牙龈注射牙周细菌后口服格列本脲并进行组织学分析。

主要发现

  • 每种牙周致病菌刺激均诱导THP-1巨噬细胞样细胞IL-1β分泌且无细胞死亡,该分泌被MCC950和z-YVAD-FMK抑制。
  • 格列本脲处理抑制培养上清中IL-1β表达并增强细胞内IL-1β表达。
  • 大鼠模型中口服格列本脲较对照组显著抑制炎症细胞浸润和牙槽骨破骨细胞数量。
  • 格列美脲抑制THP-1巨噬细胞样细胞释放IL-1β,而甲苯磺丁脲、格列齐特和二甲双胍未抑制。

关键数值与推荐

  • IL-1β和caspase-1表达通过Western blotting和酶联免疫吸附试验分析。
  • 细胞死亡通过乳酸脱氢酶试验分析。

临床怎么用

  • 提示格列本脲等靶向NLRP3通路的药物可能用于抑制牙周致病菌诱导的炎症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interleukin-1β (IL-1β) is an inflammatory cytokine produced by monocytes/macrophages and is closely associated with periodontal diseases. The NLRP3 inflammasome is involved in IL-1β activation through pro-IL-1β processing and pyroptotic cell death in bacterial infection. Recently, glyburide, a hypoglycemic sulfonylurea, has been reported to reduce IL-1β activation by suppressing activation of the NLRP3 inflammasome. Therefore, we evaluated the possibility of targeting the NLRP3 inflammasome pathway by glyburide to suppress periodontal pathogen-induced inflammation. THP-1 cells (a human monocyte cell line) were differentiated to macrophage-like cells by treatment with phorbol 12-myristate 13-acetate and stimulated by periodontopathic bacteria, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, or Fusobacterium nucleatum, in the presence of glyburide. IL-1β and caspase-1 expression in the cells and culture supernatants were analyzed by Western blotting and enzyme-linked immunosorbent assay, and cell death was analyzed by lactate dehydrogenase assay. Stimulation of THP-1 macrophage-like cells with every periodontopathic bacteria induced IL-1β secretion without cell death, which was suppressed by the NLRP3 inhibitor, MCC950, and caspase-1 inhibitor, z-YVAD-FMK. Glyburide treatment suppressed IL-1β expression in culture supernatants and enhanced intracellular IL-1β expression, suggesting that glyburide may have inhibited IL-1β secretion. Subsequently, a periodontitis rat model was generated by injecting periodontal bacteria into the gingiva, which was analyzed histologically. Oral administration of glyburide significantly suppressed the infiltration of inflammatory cells and the number of osteoclasts in the alveolar bone compared with the control. In addition to glyburide, glimepiride was shown to suppress the release of IL-1β from THP-1 macrophage-like cells, whereas other sulfonylureas (tolbutamide and gliclazide) or other hypoglycemic drugs belonging to the biguanide family, such as metformin, failed to suppress IL-1β release. Our results suggest that pharmacological targeting of the NLRP3 pathway may be a strategy for suppressing periodontal diseases.

来源:J Dent Res,查看原文。版权归原作者所有。

引用

  1. Kawahara Y, Kaneko T, Yoshinaga Y, et al. Effects of Sulfonylureas on Periodontopathic Bacteria-Induced Inflammation. J Dent Res. 2020. PMID: 32202959. doi:10.1177/0022034520913250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。